Navigation Links
StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
Date:10/17/2007

FRAMINGHAM, Mass., Oct. 17 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) today reported receipt of a $500,000 strategic investment from Inverness Medical Innovations, Inc. (Amex: IMA). In connection with this financing, StatSure and Inverness signed two additional agreements. First, the two companies signed an agreement whereby Inverness acquired an option to the exclusive, worldwide marketing and distribution rights to certain infectious disease diagnostic tests developed by StatSure that may utilize specified Inverness and/or StatSure intellectual property. If exercised by Inverness, the option provides for StatSure and Inverness to equally share development expenses and profits. StatSure and Inverness also entered into a license agreement whereby Inverness granted to StatSure a license to certain Inverness lateral flow patents for use in a rapid test to detect HIV antibodies in point-of-care markets subject to payment of royalties to Inverness. This license pertains to HIV tests using formats other than the StatSure's "barrel format" which is already being sold by Inverness and awaiting a CLIA Waiver from the FDA.

The strategic investment consists of a purchase of 1,428,572 common shares at a price of 35 cents per share. Additionally, Inverness received 5 year warrants to purchase up to an additional 1.1 million shares of the Company's stock at a price of 75 cents per share. The proceeds of this investment will be used for general corporate purposes and to fund development of other infectious disease applications for the Company's patented test format.

Steve Peltzman, StatSure's CEO and Chairman, stated: "We are delighted with the opportunity to broaden and strengthen our strategic relationship with Inverness and hope to take full advantage of these opportunities to build revenues, market share and profits."

SSUR believes it is now poised to become a key participant in the point- of-care market for infectious disease tests. The Company believes it has the simplest, safest and most reliable product platform that meets the needs of the public health clinics, doctors offices, military, insurance industry, hospitals, and potential OTC markets.

ABOUT STATSURE

StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations. Please visit our website at http://www.StatSure.com

FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements within the meaning of the federal securities laws. These statements reflect StatSure's current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors, including without limitation, the future demand for HIV testing products; our ability to successfully commercialize the products; the intensely competitive environment in the relevant markets and the risks and uncertainties described in periodic reports filed by StatSure with the Securities and Exchange Commission under the federal securities laws, including periodic reports on Form 10-Q or Form 10-QSB, as applicable, for the period ended June 30, 2007. StatSure undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE StatSure Diagnostic Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
2. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
3. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
4. First Study To Show Positive Benefit On Atherosclerosis For People With Early Signs Of Diseased Arteries
5. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
6. Materia Licenses Metathesis Catalyst Platform to Eisai
7. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
8. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... ... January 03, 2020 , ... Stay on top of current hot topics ... industries. Access to all webinars is free, so be sure to register today to ... Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , January ...
(Date:1/3/2020)... MIAMI (PRWEB) , ... January 03, 2020 , ... American ... the Hood” and the “John Wick” series. While most know him for the movies ... “Behind The Scenes” with Laurence Fishburne. The show explores a vast range of topics ...
(Date:1/1/2020)... , ... January 01, 2020 , ... ... retail franchise, recently donated $25,000 to the Children’s Tumor Foundation through its philanthropic ... Tumor Foundation 2019 Charity Golf Tournament in Orlando, Florida on October 7, 2019. ...
Breaking Medicine Technology:
(Date:1/7/2020)... ... January 06, 2020 , ... MemoryCare.com ... has announced the Best Memory Care Facilities in Lakeland, Florida. The guide identifies ... amenities. , According to the Alzheimer’s Association , 5.6 million people ...
(Date:1/7/2020)... ... January 07, 2020 , ... R3 Stem Cell is now offering ... R3 Annual Membership, is available 24/7 and includes all the stem cell and exosome ... medicine training courses in person. For the online regenerative training courses, R3 assembled all ...
(Date:1/5/2020)... , ... January 04, 2020 , ... Urban Air, the ... to FUN! The company known for endless hours of trampolining, rock climbing, dodge-balling ... at 5830 Ballenger Creek, Frederick, MD. , “We know families are looking for ...
(Date:1/3/2020)... ... January 03, 2020 , ... ... Life Care Association® Board of Directors (ALCA). Aging Life Care Professionals® have advanced ... of older adults and the disabled, and work with the family to provide ...
(Date:1/2/2020)... (PRWEB) , ... January 02, 2020 , ... ... on addressing unmet needs in the field of urology, today announced that Dr. ... UroLift® Center of Excellence. The designation recognizes that Dr. Chartrand has achieved a ...
Breaking Medicine News(10 mins):